Why Farbe Firma is the Leading Injectable Manufacturer in Belize Last Updated: 15 September 2026 TL;DR: Belize has no standalone medicines agency. Authorisation sits with the Director of Health Services inside the Ministry of Health and Wellness, and the operative instrument is the Food and Drugs (Registration, Licensing and Inspection) Regulations 2017, S.I. No. 54 of 2017. That instrument requires genuine product registration rather than a bare import permit, and it names no approved countries and no recognised regulators at all, so an Indian WHO-GMP file is admissible on its face. The lists that do exclude India belong to the regional CARPHA shortcut and to PAHO-funded procurement, not to Belizean law. Farbe Firma Pvt Ltd manufactures over 100 sterile injectables under WHO-GMP in ISO Class 5 cleanrooms in Gujarat, India, and supplies more than 30 countries. Key Takeaways Belize registers medicines under S.I. No. 54 of 2017. A product licence is mandatory and commercialising a drug without one carries a fine of up to $10,000. The orphan-drug route in regulation 5 is the only place an import authorisation replaces registration. S.I. No. 54 of 2017 contains no list of approved countries, reference authorities or recognised GMP-certificate issuers. It asks for a valid GMP certificate, a WHO-model CPP and a certificate from the competent authority in the country of origin, and is country-agnostic on its face. The real trap is regulation 8(1): a Belize product licence expires with whichever of the GMP certificate or the CPP expires first, and regulation 8(3) requires cancellation where renewal is not filed six months ahead. Belize renewals run on the Indian certificate calendar. CARPHA's Caribbean Regulatory System and the PAHO Strategic Fund are the channels closed to a CDSCO-only file. Both naming documents were read in full and CDSCO appears in neither. Introduction: What an Injectable Manufacturer in Belize Actually Has to Clear Belize is a market of 422,924 people on World Bank 2025 data, with current health expenditure of USD 309 per capita and 4.15 percent of GDP in 2023, out-of-pocket spending at 26.8 percent, life expectancy of 73.7 years in 2024 and tuberculosis incidence of 34 per 100,000 in 2024. Belize-reported imports of pharmaceutical products from India ran at USD 1.86 million in 2022, USD 2.67 million in 2023 and USD 1.63 million in 2024. Those figures set the commercial scale. They are not what decides whether an Indian injectable can lawfully be sold there. That is decided by one statutory instrument: the Food and Drugs (Registration, Licensing and Inspection) Regulations 2017, made on 25 July 2017 and gazetted on 29 July 2017 under the Food and Drugs Act, Chapter 291, as amended by Act No. 11 of 2017. Belize has no standalone medicines regulator. The competent authority defined by the regulations is the Director of Health Services or his nominee in the Ministry of Health and Wellness, working through the Drug Inspectorate Unit. Two practical points follow. The Belize Agricultural Health Authority does not regulate human medicines; its remit is plant, animal and food safety, and the single pharmaceutical reference in its Act sits inside the definition of an animal product. And because the Ministry rebuilt its website as a placeholder page in June 2025, current forms and fee confirmations are realistically obtained by writing to the Drug Inspectorate Unit rather than by download. What Sets a World-Class Injectable Manufacturer in Belize Apart A serious supplier is separated from an ordinary one by what it can put in the file on day one. Regulation 4(1) asks for a valid GMP certificate; a WHO-model Certificate of a Pharmaceutical Product, or a Certificate of Free Sale where the country of origin is outside the WHO certification scheme; a valid certificate from the competent health authority in the country of origin; an original certificate of analysis from the manufacturer's own quality control laboratory; a summary of product characteristics with finished samples, labels, primary, secondary and external packaging and the package insert; pharmacological information; and an environmental risk assessment for hormones, antineoplastics and radiopharmaceuticals. Regulation 4(2) requires every document in English, or with an English translation attached to the original. Note what that list does not contain. There is no schedule of approved countries, no roster of recognised regulators and no geographic restriction anywhere in the instrument, including both of its Forms and both of its Schedules. The grounds for refusal in regulation 6(4) are applicant delay, an unfavourable risk-benefit balance, insufficiently justified efficacy, compositional or quality failure, erroneous information, and non-compliance with the Food and Drugs, Antibiotics, Chemists and Druggists or Misuse of Drugs Acts. None of them is country-based. A CDSCO-issued WHO-GMP certificate and CoPP are admissible on the face of the regulations, and that is worth stating plainly because it is the opposite of the position in several neighbouring markets. Quality Systems Behind Every Batch Shipped to Belize Farbe Firma manufactures more than 100 sterile injectables at a WHO-GMP certified facility in Gujarat, India, with aseptic filling in ISO Class 5 environments and supply into more than 30 countries. The quality system behind a Belize consignment is the one that supports our CTD and ACTD dossiers elsewhere: validated aseptic process simulations, routine environmental monitoring, HPLC and GC assay and related-substance methods, Karl Fischer moisture determination, LAL bacterial endotoxin testing, container closure integrity testing, and ICH Q1A stability programmes with photostability under ICH Q1B. On stability an honest word is owed. WHO's stability-conditions table, in its March 2021 update, lists Belize at 30 degrees Celsius and 65 percent relative humidity. But that entry is bracketed and carries footnote 3, which means it was supplied by the IFPMA from climate literature rather than confirmed by a Belizean authority. S.I. No. 54 of 2017 specifies no stability conditions at all, and no Belize or CARICOM guidance assigning a zone was found. We therefore hold long-term data at Zone IVa conditions as a matter of prudence, and we say that it is prudence rather than a notified national requirement. Planning a Belize registration or a wider CARICOM entry? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Belize for Global Buyers The most expensive mistake in a Belize file is not a technical deficiency, it is a calendar. Regulation 8(1) provides that a product licence is valid until the expiration date of the GMP certificate or the Certificate of a Pharmaceutical Product, whichever expires first. There is no fixed term. Renewal must be filed six months before that date, and regulation 8(3) requires the authority to cancel a registration where it is not. For an Indian manufacturer this means the lifespan of a Belize registration is set by the shortest-dated Indian certificate in the file, and the renewal clock has to be run from the CDSCO calendar rather than from a Belize anniversary. We manage that clock with our partners rather than leaving it with the importer. The second thing we bring is a clear-eyed view of which doors are shut. CARPHA's Caribbean Regulatory System issues a recommendation, not an authorisation, since only a sovereign state authorises for its own market, and Belize is one of six CARICOM states that conduct marketing authorisation at all. But CRS reviews only products that already hold a marketing authorisation from a listed reference authority, or that are WHO-prequalified. The naming document was read in full in both its December 2017 and its 20 November 2020 versions and searched for India, Indian, CDSCO and Central Drugs: zero occurrences in each. WHO-GMP is not an eligibility route there. The same holds for PAHO-funded procurement, whose criteria admit WHO Prequalification, stringent regulatory authorities, or the eight Americas-only national authorities of regional reference. CDSCO is none of the three. What follows is a sequencing recommendation rather than a discouragement. The national door in Belize is open on Indian paperwork today; the regional shortcut is not. A CARPHA-archived dataset of recommended products, last modified in 2022 and therefore not a current picture, indicates that a large majority of recommended products carried Indian marketing authorisation holders, and that they reached CRS not through CDSCO but through a Chilean or Colombian marketing authorisation obtained first. That is a route we can plan with a buyer. One verified negative is worth recording alongside it: India's own bilateral brief for Belize, as on 15 July 2026, names a single agreement, on visa exemption, and no pharmaceutical, GMP-recognition or pharmacopoeia instrument at all. Neither Belize nor India appears on any PIC/S list. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Belize require product registration, or only an import permit? Registration. Regulation 3(1) of S.I. No. 54 of 2017 prohibits commercialising a drug without registration and a product licence, with a fine of up to $10,000. A separate facility licence is required for the importer, with a mandatory pre-licence inspection. The only place an import authorisation replaces registration is regulation 5, for orphan drugs. Transitional grandfathering ended on 31 October 2017 and is not available to a new entrant. Is India on a Belize list of approved countries? There is no such list. S.I. No. 54 of 2017 was read in full, including both Forms and both Schedules, and it names no approved countries, no reference authorities and no recognised GMP-certificate issuers. India is therefore not excluded by Belizean law. Where India's absence is verified is in the CARPHA reference-authority list and in PAHO procurement eligibility, neither of which is Belize's national gate. No amending instrument to S.I. No. 54 of 2017 was found, but that search was not exhaustive. What dossier format does Belize accept - CTD, ACTD or eCTD? The regulations do not say. S.I. No. 54 of 2017 prescribes Form 1 and a list of documents and is silent on CTD, ACTD and eCTD, and no Ministry guidance on format was retrievable while its website stands as a placeholder. Farbe Firma maintains CTD and ACTD-ready dossiers and supplies the regulation 4(1) documents in the Ministry's own format. We recommend confirming the format with the Drug Inspectorate Unit before compiling. What does registration cost, and how long does a Belize licence last? The instrument sets $100 per drug per importer for registration, $50 for an amendment and $50 for renewal, with facility fees including $550 for an importer of drugs and $5,000 for a manufacturing plant. Those figures come from an OCR-scanned gazette copy and should be confirmed against a clean copy before budgeting. The licence has no fixed term: under regulation 8(1) it runs to the earlier expiry of the GMP certificate or the CPP. Is the PAHO Strategic Fund a realistic channel for an Indian supplier in Belize? Not without an upgrade. PAHO's published criteria admit only products authorised by WHO Prequalification, a stringent regulatory authority, or an American national regulatory authority of regional reference. A WHO-GMP certificate alone does not qualify, and CDSCO's WHO transitional listing is scoped to vaccines rather than medicines. Belize was recorded as a signed Strategic Fund participant in a 2017 annual report and no more recent named confirmation was found, so we make no claim about current volumes through that channel. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. Email director@farbefirma.org. Request a Quote / View Products / Blog

Last Updated: September 14, 2026 TL;DR: Brunei Darussalam's governing instrument is the Medicines Order, 2007, and product registration has been mandatory since July 2012 — but we found no reference-country list published by the authority itself. The benchmark list that circulates comes from a trade guide, and India is not among the countries it names, so India's absence is reported rather than verified. The best-evidenced requirement is the import licence: the applicant must be a company registered in Brunei Darussalam with a locally based responsible person, valid one year. Dossiers are built to ACTD, which buys format reusability and not GMP recognition. Key Takeaways We found no reference-country or reference-agency list on the Ministry of Health's own product registration pages. A benchmark list naming Singapore, Malaysia, Australia, Canada, the EU centralised procedure, the United States and the United Kingdom is reported by a trade guide rather than published by the authority, and India is not among the countries named. Registration dossiers follow the ASEAN Common Technical Dossier and ASEAN Common Technical Requirements. ACTD competence buys dossier-format reusability; it does not buy GMP recognition, an inspection waiver or an abridged evaluation. The gate is the importer. The Department of Pharmaceutical Services' own import licence guideline states that any company registered under the Registry of Companies and Business Names in Brunei Darussalam is eligible to apply, and must authorise a responsible person based in Brunei Darussalam. Import and wholesaler licences are each valid one year. On halal we found no source stating that certification is a precondition for importing a non-orally-consumed medicine into Brunei Darussalam, but we could not read the 2017 amending Order that would settle it, so we treat the question as open. Introduction: What an Injectable Manufacturer in Brunei Has to Clear Brunei Darussalam is a small market by population but an unusually concentrated one, and on the sources we read the practical entry question is less about the foreign site than about which locally registered company holds the import licence a product would sit on. The governing instrument is the Medicines Order, 2007, gazetted as S 79/07, and on the Ministry of Health's own current pharmacy page it is described as operative. The Brunei Darussalam Medicines Control Authority, BDMCA, is established under section 5 of that Order and acts through the Department of Pharmaceutical Services. We should be candid that we did not read the Order itself: both Attorney General's Chambers URLs we tried returned empty documents, so what we say about its internal structure is second-hand rather than read. The right description of its status is amended, not repealed — regulations were layered under it in 2007 and again in 2010, and we found no repealing instrument. What Sets a World-Class Injectable Manufacturer in Brunei Apart On the Ministry of Health's own product registration section we found no reference-country list, no reference-agency list and no generic stringent-authority clause, and the page stops there. A benchmark-country concept does appear in secondary regulatory-consultancy material, naming Singapore, Malaysia, Australia, Canada, the European Union under the centralised procedure, the United States and the United Kingdom. India is not among the countries named and CDSCO is not named at all. That list is undated and phrased as "nations like", so we cannot tell whether it is exhaustive or illustrative. On the same trade-guide account the abridged route is restricted to products designated General Sale List, with illustrative categories running to antiseptics, lozenges, health supplements and topical preparations — none of which is a sterile injectable, so on that account the abridged shortcut would not be open to a product like ours in any event. And the WHO transitional listing for India's CDSCO is reported at maturity level three with the scope recorded as vaccines; a listing scoped to vaccines is not a listing scoped to medicines generally. We did not open the WHO list ourselves, so we report that scope rather than assert it. Quality Systems, ACTD Format and the Halal Question Brunei registration dossiers are built to the ASEAN Common Technical Dossier and the ASEAN Common Technical Requirements. Documentation is to be in English or Malay, and we found no reference to eCTD submission in Brunei, which suggests a paper and physical-media regime rather than an electronic one. ACTD competence buys dossier-format reusability, so that a dossier already structured to ACTD for another ASEAN market is structurally transferable and the CTD-to-ACTD conversion effort is reduced rather than eliminated. It does not buy GMP recognition, an inspection waiver, an abridged evaluation, or any relief from the local import-licence architecture. The ASEAN Sectoral Mutual Recognition Arrangement on GMP Inspection obliges something narrower than its name suggests: on the ASEAN Secretariat's own FAQ, member states accept certificates of a Listed Inspection Service — an ASEAN member's own inspectorate accepted by the Joint Sectoral Committee — and the benefit is expressed territorially, as no need to re-audit a facility located within the territories of a Party. We found nothing extending it to inspectorates of non-ASEAN countries. On stability we found no climatic-zone table we could read that names Brunei Darussalam, so we do not assert a zone for it; what we can report is that the ASEAN stability guideline requires 30 °C at 75% relative humidity for long-term storage in climatic zone IV. ISO Class 5 filling, HPLC and GC assay, LAL endotoxin testing and Karl Fischer water determination sit underneath that evidence. Working out whether Brunei Darussalam is reachable for your product? Talk to our regulatory team Why Farbe Firma Is the Trusted Injectable Manufacturer in Brunei for Global Buyers Product registration is mandatory: on the Ministry of Health's own page, since the mandatory implementation of the drug registration system in July 2012, pharmaceutical importers, wholesalers and manufacturers must register a medicinal product before it can be marketed in Brunei Darussalam. An approved product is described as receiving a Product Licence Certificate valid for five years, reported by a trade guide rather than published by the authority. On whether BDMCA registers or inspects the overseas manufacturing site, and which foreign GMP certificates it accepts, we found no BDMCA-published document addressing it in either direction. Where the evidence is firm is the import licence. The Department of Pharmaceutical Services' import licence guideline, third edition dated October 2017 and currently published on the Ministry's website, states that any company registered under the Registry of Companies and Business Names in Brunei Darussalam is eligible to apply and must authorise a responsible person based in Brunei Darussalam. Read that precisely: the guideline gives Director, Manager, Pharmacist or Sales Manager as examples, so a pharmacist is one of four illustrations and not, on this text, a stated mandatory qualification. Import and wholesaler licences are each valid for one year, and approval to import is subject to the validity of the product's Product Licence — two clocks running at different speeds. The importer's standing duties are where a CDMO relationship is actually tested. Under the Second Schedule duties reproduced in that guideline, a licence holder must notify the Authority of any change in the specification of the medicinal product, in any of its constituents, in its composition or in its manufacture. A change of manufacturing process on our side is therefore a notifiable event on our importer's licence, so change control has to reach across the relationship rather than stopping at our gate. A change to another company holding no existing import or wholesaler licence requires a fresh application by that company, so switching Brunei partners is a new licensing exercise rather than a transfer. As a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries and working in CTD and ACTD format, that is the discipline Farbe Firma is built to supply. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Brunei Darussalam recognise Indian regulatory approvals? We found no published list of recognised foreign regulators on the Ministry of Health's own pages. A benchmark-country list reported by a trade guide names Singapore, Malaysia, Australia, Canada, the EU centralised procedure, the United States and the United Kingdom, and India is not among them. That list is undated and reported rather than published by the authority, so India's absence is reported and not verified. Is halal certification required for injectables imported into Brunei Darussalam? The Halal Certificate and Halal Label Order, 2005 defines "food" to include medicine expressly; but on the 2005 text we read, its application provisions are permissive and its offences attach to making a halal representation without the corresponding certificate, which is a claim-gated regime. The 2017 Amendment Order that may have changed this returned an empty document and we did not read it. The most specific account available to us, a July 2017 business-news report of a ministry briefing, states that pharmaceutical products not orally consumed may be certified but that the procedure for them is voluntary. We would treat the question as open until a Brunei-based regulatory adviser confirms it in writing. Does the ASEAN GMP mutual recognition arrangement cover an Indian manufacturer? On the ASEAN Secretariat's own FAQ, the recognition obligation attaches to certificates of a Listed Inspection Service, which is an ASEAN member's own inspectorate accepted by the Joint Sectoral Committee, and the no-re-audit benefit is expressed as applying to facilities located within the territories of a Party. India is not an ASEAN Member State, and we found nothing extending the Arrangement to inspectorates of non-ASEAN countries. Who has to hold the Brunei import licence? The Department of Pharmaceutical Services' import licence guideline states that any company registered under the Registry of Companies and Business Names in Brunei Darussalam is eligible to apply, and that the company must authorise a responsible person based in Brunei Darussalam. On whether the Product Licence holder must itself be locally incorporated we found no BDMCA-published statement either way. How are medicines bought by the public sector in Brunei Darussalam? On the United States International Trade Administration's February 2024 country commercial guide, individual ministries conduct their own procurement under regulations issued by the State Tender Board at the Ministry of Finance and Economy. We found no Brunei government e-procurement portal and no e-tender platform named in any source we read. The practical reading is that procurement is downstream of licensing, because only a company registered in Brunei Darussalam holding an import or wholesaler's licence may import, store and sell the product by wholesale. Technically Reviewed By: Maulik Sudani & Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote / View Products / FAQ / Blog

Last Updated: September 14, 2026 TL;DR: The Maldives Food and Drug Authority publishes a named list of Reference Regulatory Authorities in Annexure-I of its Guideline on Good Reliance Practice. We read all 45 entries and India is not among them, though MFDA itself describes the list as dynamic and subject to change. Reliance pathways are mandatory for parenterals; a WHO-GMP certificate issued by an Indian state licensing authority is not one of the enumerated grounds for exempting a foreign site from inspection; and the licence that can stop a shipment sits on the Maldivian importer's registered medicine warehouse. Key Takeaways MFDA publishes its reference list as Annexure-I to its Guideline on Good Reliance Practice, verified on 18 July 2024. We read all 45 entries and India is not among them, though section 6.3.1 calls the annexure a dynamic list subject to change. A second annexure, Annex II of the 176-page registration guideline, we did not reach, so the two must be kept apart. Section 6.3.4 of the registration guideline makes reliance pathways mandatory for high-risk products "like parenteral", so on that wording a sterile injectable cannot elect the full-dossier route as of right. On the exemption criteria we read in section 10.1.1, an Indian state licensing authority's WHO-GMP certificate is not among the grounds for exempting a foreign site from inspection. The binding constraint is the Maldivian importer's registered medicine warehouse — a minimum of 200 square feet on MFDA's import guideline, inspected, MVR 1,200 to register — and if renewal is not filed before expiry the warehouse "shall be removed from the Authorized Importers List". Introduction: What an Injectable Manufacturer in Maldives Must Clear First MFDA states the market's basic condition in its own import guideline: "Due to inadequate capacity to manufacture, Maldives is a 100% importing country with regard to medicine." WHO's 2025 pharmaceutical country profile records the number of private pharmaceutical manufacturers in the Maldives as "None". Every vial of a sterile injectable reaching a Maldivian hospital has crossed a border first, so whose regulatory decisions MFDA will lean on is an opening question for an exporter. That question has a published answer. MFDA publishes its Reference Regulatory Authorities in Annexure-I of its Guideline on Good Reliance Practice for Regulation of Medicines, a document its Medicine and Therapeutic Goods Technical Committee verified on 18 July 2024. We read that annexure in full: 45 numbered entries, spanning Australia, Canada, Japan, Singapore, Switzerland, the United Kingdom, the United States and much of the European Union and EEA. India is not among the 45 entries we counted, and the Central Drugs Standard Control Organisation is not named anywhere in that annexure. MFDA describes the annexure, in section 6.3.1, as "a dynamic list and is subject to change by MFDA as needed", so India's absence describes the document we read in September 2026 rather than the one that will exist later. What Sets a World-Class Injectable Manufacturer in Maldives Apart The practical work sits in section 10.1.1 of MFDA's Guideline on Good Reliance Practice, which governs GMP verification for a site outside the Maldives. Importers are "exempted for inspection of manufacturing unit abroad" if the product qualifies under a listed set of criteria. Those we read include registration with a Reference Regulatory Authority in Annexure-I; registration with at least three of the authorities the clause calls "former Eastern Europe"; a GMP certificate retrievable on the EUDRA-GMDP website; a WHO-prequalified product together with the facility that makes it; and a product approved by, or a site inspected by, a PIC/S Participating Authority. India is not a PIC/S participating authority and CDSCO does not appear on the Annexure-I list we read, so a WHO-GMP certificate issued by an Indian state licensing authority is not, on the face of those criteria, one of the enumerated exemption routes. The certificate remains part of the evidence package, but no clause we read treats it, on its own, as a ground for exempting the site from inspection. MFDA operates a risk-based exemption rather than a blanket exclusion and reserves its position expressly, providing that it "may conduct risk based GMP inspection of the manufacturing facility any time (before or after grant of approval)". Quality Systems Behind Every Sterile Injectable — and the Zone IVA Question MFDA names a climatic zone, and the zone it names is IVA rather than IVb. Its Guideline on Good Reliance Practice provides at section 7.1.2 that reliance on a Reference Regulatory Authority's assessment is subject to the availability of quality data "pertaining to Zone IVA conditions (if required)", and at section 9.1(a) that stability studies should be "as per Zone IVA (for pharmaceutical)". Where Zone IVA data are not available, the same clause asks for a commitment and protocol for studies under the appropriate climatic conditions. The 176-page registration guideline enumerates the ICH zones from I to IVB but, in the portion we read, does not assign the Maldives to any one of them. We searched the WHO and ICH text of the Q1F stability guideline for "Maldives" and found no occurrence, so we found no table that names the Maldives and assigns it a zone. The statement we can support is the narrower and more useful one: MFDA's own reliance guideline asks for Zone IVA data by name. ISO Class 5 filling, HPLC and GC assay, LAL endotoxin testing and Karl Fischer water determination are the capabilities that make that evidence possible to assemble; they are not themselves the gate. Working out whether the Maldives is reachable for your product? Talk to our regulatory team Why Farbe Firma Is the Trusted Injectable Manufacturer in Maldives for Global Buyers Start with who holds the registration, because it is not the foreign manufacturer. Every application under the registration guideline's table must carry a Letter of Appointment together with a letter from the manufacturer to MFDA, and that appointment is how a Maldivian party takes on the manufacturer's responsibilities for the product. On our reading of the Dhivehi text of Medicine Regulation R-64/2026, Article 11(b) provides that only a Maldivian citizen or a legal person with Maldivian shareholding may submit a registration application. We found no official English translation, so that reading should be confirmed with MFDA before it is relied on commercially. Then the licence that can actually stop a shipment. MFDA's Guideline for Authorization of Medicine Import, issued 23 June 2022, makes a registered medicine warehouse the prerequisite for an import licence, with applications running through the Dhirithi Portal and the guideline stating that "the floor area of a medicine warehouse shall be minimum 200 square feet." The renewal rule belongs in a partner agreement: if a renewal request has not been submitted before the permit expires, the warehouse "shall be removed from the Authorized Importers List" and the importer files a fresh application rather than a renewal. Registration is necessary and not sufficient, and the last gate is commercial. WHO's 2025 profile records public-sector procurement as centralized, naming the State Trading Organization for public-sector pharmacies and the Ministry of Health for hospital-use medicines. MFDA's Approved Drug List then divides the market again: its legend reserves some products to national programmes or to designated importers, and marks others as restricted to hospital and institutional use, which "cannot be kept for sale in pharmacies" — so being on the list does not by itself establish who may buy. As a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries and working in CTD and ACTD format, what Farbe Firma contributes is evidence a Maldivian partner can file: batch documentation, stability data referable to Zone IVA, and change control that survives an inspection request arriving after approval. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Is India on the Maldives Food and Drug Authority's reference list? Not on the list we read. MFDA publishes its Reference Regulatory Authorities as Annexure-I to its Guideline on Good Reliance Practice, verified on 18 July 2024, and India is not among the 45 entries we counted, nor is CDSCO named in that annexure. Two qualifications: section 6.3.1 describes the annexure as a dynamic list subject to change, and a second annexure, Annex II of the 176-page registration guideline, is pointed at by a different MFDA document that our extraction did not reach. Does the Maldives accept the Indian Pharmacopoeia? Section 11.2(e)(i) of the registration guideline requires every ingredient to be listed with its pharmacopoeial standard, "i.e., British pharmacopeia (BP), US pharmacopeia (USP) or Indian pharmacopeia (IP) or any pharmacopeia of stringent regulatory authorities". That is acceptance of IP as a book of standards against which a specification may be written. Recognition of a pharmacopoeia is not recognition of the agency that publishes it, and nothing in that clause places India on a reliance pathway. MFDA's own documents also expand IP differently — "Indian pharmacopeia" in one guideline, "International Pharmacopoeia" in the other. Is a WHO-GMP certificate enough for MFDA to accept an Indian manufacturing site? Not on its own, on the criteria we read. Section 10.1.1 of the reliance guideline enumerates the grounds for exempting a foreign manufacturing unit from inspection, and an Indian state licensing authority's WHO-GMP certificate is not among them. The routes that remain visibly open are WHO prequalification of the product together with the facility that makes it, inspection by a PIC/S participating authority, registration with at least three of the authorities the clause calls former Eastern Europe, a qualifying inspection by another NRA within three years, or an MFDA inspection of the site itself. Which regulation governs a Maldivian registration filed today? That is a question to put to MFDA in writing, because the answer is changing. Medicine Regulation R-64/2026 was gazetted on 25 July 2026 and MFDA's download page states that it takes effect 90 days later, on 23 October 2026, so as at September 2026 it is published but not commenced. MFDA's operative guidelines still cite R-46/2014 and amendment R-49/2016, while its Laws and Regulations download category offers only R-64/2026. Article 72 of R-64/2026 is headed with the Dhivehi for regulations repealed, but we could not read the instruments it names. What does a Maldivian partner actually need in place? A registered medicine warehouse and a current entry on the Authorized Importers List, which MFDA's import guideline says is published every four months. The warehouse is inspected, the guideline states a minimum floor area of 200 square feet, and registration or re-registration is invoiced at MVR 1,200. Technically Reviewed By: Maulik Sudani & Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote / View Products / FAQ / Blog

Last Updated: September 13, 2026 TL;DR: Cabo Verde's medicines regulator is ERIS, created by Decreto-Lei n.º 03/2019 de 10 de janeiro, which extinguished ARFA — so any guidance naming ARFA is stale. ERIS publishes two reference-entity lists and India's CDSCO is on neither by name. Its only possible entry runs through WHO's maturity-level list, where WHO's scope for CDSCO reads Vaccines (producing). The full dossier route is open, and the recognition rules set WHO GMP equivalence as the benchmark. Key Takeaways ERIS, the Entidade Reguladora Independente da Saúde, was created by Decreto-Lei n.º 03/2019 de 10 de janeiro and extinguished ARFA, the Direção Geral de Farmácia and the Inspeção Geral da Saúde. Guidance naming ARFA as the licensing authority describes a body abolished in January 2019. India's CDSCO appears on neither of the two reference-entity lists ERIS publishes. Its only possible entry is the 2025 annex's first category, a hyperlink to WHO's maturity-level list — where WHO's scope for CDSCO reads Vaccines (producing), with no medicines line. The list is not closed. Article 5 of Deliberação n.º 03/2019 admits another regulatory authority meeting the requirements of article 6, and article 6 sets the GMP benchmark at norms at minimum equivalent to those published by WHO. That is an argument to put to ERIS in writing, not an entitlement. Article 9(e) wants GMP evidence issued by an entity recognised by ERIS, and the only express fallback covers the active-ingredient maker alone. Physical import runs through the two licensed importer-distributors on the regulator's own register. Introduction: What an Injectable Manufacturer in Cape Verde Has to Prove Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? Cabo Verde names a great many, twice over, and India is on neither list. ERIS publishes a reference-entity list dated 31 December 2020 and, beside it, the annex to Deliberação n.º 06/2025 de 14 de março, last updated in March 2025. Neither page says which one governs, and India's CDSCO appears on neither by name. There is one indirect door and it is narrower than it looks. The 2025 annex's first category is not a list ERIS wrote but a hyperlink to WHO's own list of authorities at maturity levels 3 and 4 — and WHO's entry for India's CDSCO carries the scope Vaccines (producing), with no medicines line beside it. Whether ERIS would accept a CDSCO decision on a non-vaccine product through that category is unresolved on the documents we have, and it is a question to put to the regulator in writing rather than to assume. What Sets a World-Class Injectable Manufacturer in Cape Verde Apart Start with the regulator, because half the guidance in circulation names a body that no longer exists. ERIS — the Entidade Reguladora Independente da Saúde — was created by Decreto-Lei n.º 03/2019 de 10 de janeiro, published in Boletim Oficial n.º 03, I Série, 1.º Suplemento, and it extinguished ARFA, the Direção Geral de Farmácia and the Inspeção Geral da Saúde in one stroke. The older regulations survive, because article 3(4) provides that legal references to ARFA are deemed made to ERIS. ERIS's own authorisation page still answers its legal-framework question by naming a 2014 deliberation that was expressly revoked in 2019, so read the instruments rather than the guidance. Then read article 5 of Deliberação n.º 03/2019 carefully, because it is the most useful sentence in the file. Recognition is available where an authorisation exists from an entity ERIS recognises or another regulatory authority that meets the requirements of article 6 — and article 6 asks only for an official authority that evaluates and authorises medicines, and one that guarantees by inspection that GMP norms at minimum equivalent to those published by WHO are respected. WHO GMP equivalence is ERIS's own express benchmark. A WHO-GMP holder has a textually grounded argument there; it has to be made in writing, and it is not self-executing. Quality Systems Behind Every Sterile Injectable We Ship to Cape Verde Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Dossiers are built in CTD structure with ACTD available — useful raw material here, though we found no provision making CTD or eCTD mandatory: article 10 asks for ERIS's own folder structure, distributed as a template from its site, and we found no e-submission portal. The stability requirement is stated in the regulation itself and it is the detail most often got wrong. Article 8(1)(i) requires studies adequate to the climatic zone of Cabo Verde, named as Zona Climática IVA in line with WHO guidance and conducted per ICH — not IVB. ERIS also accepts, as an alternative to completed results, a declaration that studies have been initiated together with the protocol, which is a real concession on timelines. On sample quantities we found no provision anywhere in the recognition regulation, and no guideline language calling any quantity approximate; we did not open the full-dossier regulation, where any such requirement would sit. Working out whether Cape Verde is reachable for your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Cape Verde for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Cabo Verde we can supply the WHO-format CPP, the GMP and manufacturing-authorisation evidence, Zone IVA stability packages and the certified Portuguese translations the labelling texts need. The hardest gate is article 9(e), which wants GMP evidence issued by an entity recognised by ERIS, and whose only express fallback covers the active-ingredient maker alone. We hold no Cabo Verdean authorisation and recommend no partner we have not verified. Sterile injectables are structurally an import category here, and the register shows why. ERIS's list of licensed national operators, last updated 31 July 2026, names exactly one manufacturer in the country, Laboratórios INPHARMA, and we found no evidence that it manufactures sterile injectables — its own description of its production covers solid, liquid and semi-solid forms, and the only certification it names on its own site is ISO 9001. Physical import and wholesale distribution run through the two licensed importer-distributors on that same register, EMPROFAC, whose authorisation reference dates it to 1979, and SODIFAR, authorised in 2022. A foreign holder need not be seated in Cabo Verde: article 9(b) asks for proof of registration in the country where the applicant has its seat. The scale is small and the geography does the rest. Population is published at 491,233 by the national statistics institute for 2021 and at 527,326 by the World Bank for 2025 — about 7% apart, so we give both. Our own approximate calculation of national health spend, multiplying a 2025 population by a 2023 per-capita figure, lands between about US$142 million and US$153 million a year, and it is indicative only. Our own approximate count of the July 2026 register is 41 licensed private pharmacies across nine inhabited islands — twenty on Santiago, one each on Maio and Brava. For a 2 to 8 °C product that thin end of the network is a single point of cold storage per island, and every unit crosses water twice. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Is India's regulator recognised by Cape Verde? Not by name. India's CDSCO appears on neither of the two reference-entity lists ERIS publishes — neither the list dated 31 December 2020 nor the annex to Deliberação n.º 06/2025 updated in March 2025. The 2025 annex reaches India only indirectly, through a category defined by a hyperlink to WHO's list of authorities at maturity levels 3 and 4, and WHO's scope for CDSCO there reads Vaccines (producing), with no medicines line. Whether ERIS would accept a CDSCO decision on a non-vaccine product is unresolved on the documents we have. So is Cape Verde closed to Indian manufacturers? No. The full self-standing dossier route, AIM por processo completo under Deliberação n.º 06/2016 de 6 de maio, is open to any applicant whichever regulator authorised the product elsewhere — we did not obtain its procedural detail. And the recognition regulation carries its own catch-all: article 5 admits another regulatory authority that meets the requirements of article 6, and article 6 sets the GMP benchmark as norms at minimum equivalent to those published by WHO. A WHO-GMP holder has an argument to make there, in writing. What does registration cost in Cape Verde, and how long does it take? ERIS publishes 60,000 CVE for an especialidade farmacêutica and 25,000 CVE for a medicamento genérico, per medicine, where a medicine means name plus INN plus pharmaceutical form plus strength — and grouping strengths into one application does not reduce the number of fees. On timing, article 12 gives ERIS 90 calendar days from entry, extendable once by 60, but the clock suspends whenever the file is incomplete or ERIS queries the originating authority. It is a statutory period, not an elapsed-time forecast, and we found no published timeline for the full-dossier route. Must the dossier be in Portuguese, and must it be in CTD format? Portuguese is required for the application petition itself, and the summary of product characteristics, patient leaflet and labelling text must be supplied in certified Portuguese translation and additionally in editable form. Most of the technical file — the WHO-format CPP, quality-control methods and specifications, manufacturing authorisations, GMP certificates, the site flow chart — is accepted in Portuguese, English or French, so an English technical file is largely usable as it stands. We found no provision making CTD or eCTD mandatory, and no e-submission portal. Can the African Medicines Agency or ECOWAS get a product into Cape Verde? Not AMA, not yet. The treaty entered into force on 5 November 2021 and Cabo Verde acceded on 28 April 2023 and deposited on 13 July 2023, though it never signed — but we found no AMA-issued marketing authorisation, no published joint-assessment procedure and no submission portal, and AMA's own Director-General says it cannot yet function as a full single channel. ECOWAS is different: the West African joint assessment produces a WAHO recommendation, not an authorisation, and ERIS expressly names it on both of its recognition lists. Technically Reviewed By: Maulik Sudani & Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote / View Products / FAQ / Blog

Last Updated: September 13, 2026 TL;DR: Suriname has no standalone medicines agency. Marketing authorisation is granted by the Registratiecommissie der geneesmiddelen, which the Ministry of Health calls a working organ of the Ministry of Health, under an Ordinance of 8 May 1896 that is still operative as amended. Its fast track names eleven countries and four further categories, and India is not among them. The full dossier route stays open — on paper, in Dutch or English, filed by a licensed Surinamese importer. Key Takeaways There is no standalone drug agency. Authorisations come from the Registratiecommissie der geneesmiddelen, which the Ministry of Health calls a working organ of the Ministry of Health and whose own Code of Conduct describes it as a sub-commission of a Medicines Commission. The fast-track letter of 16 August 2022 names eleven countries and four further categories — fifteen numbered items. India is not among them, and we found no source placing CDSCO on the PIC/S members list, so that category does not reach India either. Instruction DVG 189/'25 of 19 February 2025 reserves a power to require an independent, GLP-compliant laboratory report applying to every batch, where the manufacturer has not registered or marketed the product in a country the instruction calls highly regulated. Registration is not permission to import. A separate import licence comes from the Ministry of Economic Affairs and is approved by the Pharmaceutical Inspectorate, and we found no published route for a foreign manufacturer to file in its own name. Introduction: What an Injectable Manufacturer in Suriname Has to Prove Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? Suriname names eleven of them. A letter from the Registration Commission to importers, reference 019/2022 and dated Paramaribo, 16 August 2022, lists the Netherlands, England, Germany, Canada, USA, Belgium, France, Switzerland, Norway, Denmark and Sweden, and then four further categories. India is not among them, and we found no source placing CDSCO on the PIC/S members list either. That is a narrower finding than it sounds. Products from all other countries are expressly provided for, and the route they take is open. The Commission's own Code of Conduct says it assesses on the principle of reliance, so being off the reliance list means a heavier file and a slower lane rather than a closed door. Two of the four further categories — WHO prequalification, and a Caribbean Regulatory System recommendation — name no country at all and stay available product by product. What Sets a World-Class Injectable Manufacturer in Suriname Apart The first thing to get right is who the regulator is, because most secondary write-ups get it wrong. Suriname has no standalone medicines agency. Marketing authorisations are granted by the Registratiecommissie der geneesmiddelen, described by the Ministry of Health as a working organ of the Ministry of Health and by its own Code of Conduct as a sub-commission of a Medicines Commission, with at most seven expert members appointed by the President of the Republic. Its legal basis is the Ordinance of 8 May 1896 regulating the practice of pharmacy, operative text G.B. 1960 no. 77, amended several times since — amended, not repealed. The second is that the dossier is not the one you already have. The regulator calls its annex scheme the Common Technical Dossier, Appendices A to K — one word away from ICH's Common Technical Document, and not the same thing. It is an eleven-item Surinamese list running from quantitative composition of the actives to a statement from the competent authority in the country of production, and it asks along the way for data under tropical conditions and for labels and packaging material in six-fold. We found no published statement that an ICH CTD, ACTD or eCTD dossier is accepted in its place. Quality Systems Behind Every Sterile Injectable We Ship to Suriname Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Stability follows ICH Q1A with Q1B photostability. Dossiers are built in CTD structure with ACTD available — here they are the raw material for the A to K annexes rather than the filing itself, and the full route wants the WHO-GMP certificate of the API manufacturer as well as of the finished-product site. Two local details shape the work more than any of that. Both routes require a physical sample with the package leaflet enclosed, showing the country-of-origin registration number; the full route adds a certificate of analysis of that sample, and Annex J asks for samples of the finished dosage form and of the active ingredients in sufficient supply for analysis. For a short-dated parenteral that is a logistics exercise, and the regulator states that for now it is not possible to submit a registration file electronically. On cold chain we found no published Surinamese distribution or temperature guideline, and therefore claim none. Working out whether Suriname is reachable for your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Suriname for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Suriname we can build the A to K annex set, supply the CPP and the WHO-GMP certificates of both the finished-product and the API sites, and generate the stability, release and sample data the file needs. What we cannot do is lodge it. The instructions are addressed to importers, the submitting party must hold a wholesale distribution authorisation and be registered with the Pharmaceutical Inspection Department as an importer, and the cover letter must be signed by the importer's director and by the consultant pharmacist. We hold no Surinamese registration and recommend no partner we have not verified. The bilateral relationship is unusually warm, and it is routinely oversold. Diplomatic relations date from 1976, the Government of India's own embassy in Paramaribo puts the Indian-origin community at over 27% of the population, more than 550 ITEC training slots have been used, and lines of credit run cumulatively to the tune of US$60 million. On 4 June 2023 the Indian Pharmacopoeia Commission and Suriname's Ministry of Health signed a Pharmacopoeia MoU under which, in the IPC's own words, IP is accepted as a book of standards for medicines in the Republic of Suriname. That is standards recognition, not regulatory reliance. It did not place India on the 2022 fast-track list, which we found unamended, and it waives none of the CPP, the two GMP certificates, the annexes or the sample certificate of analysis. The numbers are small, and the honest version of them is worth more than a round one. India's embassy puts the population at about 620,000 while UN-based projections carried by population trackers put it nearer 645,000 for 2026, and we report both because they disagree. State supply runs through BGVS, the state medicines company established on 4 February 1983 and described on its own site as the country's largest importer and wholesaler of medicines; SZF, the social health insurer, publishes 271 medicines and consumables on which no patient co-payment may be charged. Our own approximate and partial count of the national medicines list, taken from its own export and covering entries from Abacavir to Doxycycline only, found about 202 product entries of which about 62 are injectable dosage forms — roughly three in ten. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Suriname recognise India's CDSCO or Indian regulatory approval? Not on the fast track. The Registration Commission's letter to importers names eleven countries — Netherlands, England, Germany, Canada, USA, Belgium, France, Switzerland, Norway, Denmark and Sweden — plus four further categories, and India is not among them; we also found no source placing CDSCO on the PIC/S members list. An Indian-made product can still reach the fast track product by product, through WHO prequalification or through a CARPHA Caribbean Regulatory System recommendation. Is the Indian Pharmacopoeia accepted in Suriname? Yes, as a book of standards. The Pharmacopoeia MoU signed on 4 June 2023 means, in the Indian Pharmacopoeia Commission's own words, that IP is accepted as a book of standards for medicines in the Republic of Suriname. Keep it in proportion: that is compendial recognition, useful in the composition and testing sections of a dossier. It is not regulatory reliance on CDSCO, and we found nothing designating CDSCO as a reference authority for Suriname. Can we submit a Suriname dossier in ICH CTD format? The regulator's published scheme is its own eleven-item annex list, which it calls the Common Technical Dossier, Appendices A to K — confusingly close to the ICH Common Technical Document, and not the same thing. We found no published statement that an ICH CTD, ACTD or eCTD dossier is accepted in its place, so plan for A to K. The regulator also states that for now it is not possible to submit a registration file electronically, so filings are hard copy. Will Suriname require independent batch testing of our injectables? It may. Ministry of Health instruction DVG 189/'25, dated 19 February 2025, reserves the power — where the manufacturer has not registered or marketed the product in a country the instruction calls highly regulated — to require an analysis report from an independent, GLP-compliant laboratory approved by the regulator of the country of manufacture, applying to every batch for which registration is sought. It defines highly regulated by PIC/S membership, WHO prequalification and WHO Listed Authorities, and allows a waiver on risk assessment. It is a reserved power exercised case by case, not a blanket rule. Can we register in Suriname without a local partner? The instructions are addressed to importers and state that the submitting party must have a wholesale distribution authorisation and be registered with the Pharmaceutical Inspection Department of the Ministry of Health as an importer of medicinal products, with the cover letter signed by the importer's director and by the consultant pharmacist. We found no published route for a foreign manufacturer to file in its own name. Separately, a registered product still needs an import licence from the Ministry of Economic Affairs, approved by the Pharmaceutical Inspectorate. Technically Reviewed By: Maulik Sudani & Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote / View Products / FAQ / Blog

Last Updated: September 12, 2026 TL;DR: Bhutan rewrote its medicines rulebook seven months ago. The Bhutan Medicines Rules and Regulation 2025 came into force on 21 February 2026 and superseded the 2019 edition, and the regulator has not been the Drug Regulatory Authority since 2022 — it is the Bhutan Food and Drug Authority. Bhutan names the Indian Pharmacopoeia as an accepted standard and trades with India duty-free. What it does not do is give Indian regulatory approval any reliance benefit. Key Takeaways The Bhutan Medicines Rules and Regulation 2025 took effect on 21 February 2026, superseding the 2019 edition. Any guidance still naming the Drug Regulatory Authority describes a regime that no longer exists. The abridged route keys off WHO-Listed Authority status, transitional WLA status or WHO prequalification, and names no agency at all. CDSCO's transitional listing is scoped to vaccines, so it earns an Indian injectable nothing here. The Indian Pharmacopoeia is named — one of six pharmacopoeias accepted by the current registration guideline. That recognition sits in guidance, not in the Act or the Rules, which name none. A Bhutanese entity must hold the Market Authorization; a foreign manufacturer cannot. Free trade with India removes the tariff and the currency risk, not the local-partner requirement. Introduction: What an Injectable Manufacturer in Bhutan Has to Prove Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? Bhutan answers inside a rulebook seven months old. The Bhutan Medicines Rules and Regulation 2025 came into force on 21 February 2026 and expressly superseded the 2019 edition. The regulator changed earlier and more quietly: the Drug Regulatory Authority was folded into the Bhutan Food and Drug Authority under the Civil Service Reform Act of Bhutan 2022. Read what the new regime says rather than what it suggests. The abridged route opens only where a product is registered by a WHO-Listed Authority or a transitional WLA, or prequalified by WHO — and the guideline names no authority anywhere. CDSCO sits on WHO's transitional list for vaccines, not for medicines, so an Indian approval carries an injectable through none of those limbs. The standard route stays fully open; it simply confers no shortcut. What Sets a World-Class Injectable Manufacturer in Bhutan Apart The distinction that matters most here is between a reliance test and a certificate test. Bhutan's standard route asks for proof of foreign approval — a country-of-origin marketing authorisation, an assessment report, or a Certificate of a Pharmaceutical Product in WHO format. An Indian manufacturer satisfies that comfortably, and it buys no abridgement. The one genuine shortcut open to an Indian plant is a BFDA audit of the site itself, graded at the authority's top level, and that route is restricted to medicines on Bhutan's essential medicines list. The second thing worth knowing is that Bhutan names the Indian Pharmacopoeia. The current registration guideline accepts six pharmacopoeias — British, United States, Indian, International, Japanese and European — and requires the edition relied on to have issued within the last five years. Keep it in proportion, though: neither the Medicines Act nor the Rules names any pharmacopoeia, so the recognition rests on a guideline the authority can revise without legislation. Quality Systems Behind Every Sterile Injectable We Ship to Bhutan The dossier Bhutan asks for is largely the dossier a serious sterile plant already generates. Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Stability follows ICH Q1A with Q1B photostability. Dossiers are built in CTD structure with ACTD available — Bhutan accepts either. Two details change how the file is assembled. A Site Master File in WHO format is mandatory for foreign manufacturers and is not asked of domestic ones, so it is a workstream to schedule rather than an afterthought. And Bhutan waives bioequivalence data for simple aqueous intravenous solutions and powders for reconstitution, which covers much of a sterile injectable portfolio. On storage conditions we found no published Bhutanese climatic-zone assignment, and therefore claim none. Working out whether Bhutan is reachable for your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Bhutan for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Bhutan we can build the CTD or ACTD dossier, supply the WHO-format CPP and Site Master File, and generate the stability and release data the file needs. What we cannot do is hold the registration: the Rules restrict applications to a Bhutan-based manufacturer, a licensed wholesale pharmacy or a government procurement agency. We hold no Bhutanese registration and recommend no partner we have not verified. The commercial frame is unusually favourable and widely misdescribed. The India–Bhutan Agreement on Trade, Commerce and Transit establishes a free trade regime, and bilateral trade is invoiced in Indian Rupees at par with the Ngultrum — no tariff line to negotiate and no currency exposure. Note what that does not mean. Bhutan is a WTO observer rather than a member, so it carries no TRIPS obligations, and free trade in goods does not license entry of an unregistered medicine. The numbers are small, and being straight about them matters more than the size. Population was 791,524 in 2024 on World Bank figures; current health expenditure was 4.42% of GDP in 2023 and US$162 per head, putting the entire national health budget near US$128 million. Government financing rose to 66.65% in 2023 while external financing fell to 6.44% — a donor unwind, not a spending surge. Bhutan's own customs data put India at 75.1% of pharmaceutical imports in 2024, so the familiar claim of total dependence overstates it. We will not print a market-size figure: the two available sources differ by nearly twice. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Bhutan recognise India's CDSCO or Indian regulatory approval? Not for reliance purposes. The abridged route turns on WHO-Listed Authority status, transitional WLA status or WHO prequalification and names no agency, while CDSCO's transitional listing is scoped to vaccines rather than medicines. What Bhutan does accept from India is proof of foreign approval — a country-of-origin marketing authorisation or a WHO-format Certificate of a Pharmaceutical Product. That is a requirement about document format, not about which regulator signed it. Is the Indian Pharmacopoeia accepted in Bhutan? Yes — one of the few markets in this series where the answer is a clean yes. The current registration guideline lists six acceptable pharmacopoeias and the Indian Pharmacopoeia is among them, provided the edition relied on issued within the last five years. The qualification worth carrying is that neither the Medicines Act nor the Rules names any pharmacopoeia, so the recognition is guideline-level and revisable by the authority. Does a foreign manufacturer need a local partner in Bhutan? Yes. The Rules restrict applications to a Bhutan-based manufacturer, an authorised sale-and-distribution premises or a government agency, and the standard authorisation letter requires the holder to have an office in Bhutan, naming it sole dealer and accountable for the product. One point has changed: since February 2026 an importer that is not the authorisation holder may import for sale with a no-objection certificate from that holder. What does registration cost in Bhutan, and how long does it take? Both answers are currently published twice, differently, by the same regulator. The fee schedule in the 2025 Rules sets a single Nu. 2,000 market-authorisation fee, while the authority's own FAQ page still shows Nu. 500 plus Nu. 1,500 from the pre-merger era. On timing, the guidelines give a 60-day turnaround that runs on a stop-clock and pauses for every query round, while the same FAQ says two to three months. Confirm both directly with BFDA. What actually controls an injectable consignment arriving in Bhutan today? The import authorisation, issued per consignment rather than per product. It covers a single import — six months for an unregistered product, and a year or the remaining registration validity for a registered one — and the current schedule prices it at Nu. 200. Narcotics and psychotropics run on a separate and stricter track through a different division, needing a fresh authorisation for every shipment. A supplier describing one standing import licence is reading something that is not there. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 12, 2026 TL;DR: Solomon Islands has no medicines register. The Pharmacy and Poisons Act has been in force since 1941 and licenses sellers and premises, not products, so there is no dossier to file. Section 43 makes the British Pharmacopoeia the standard of quality for every medicine sold. What actually binds a consignment is the importer's own licence, the Ministry's tender, and the donor rules attached to malaria and tuberculosis money. Key Takeaways There is no product registration system. The Act creates registers of pharmacists and of premises, and none for medicines. Anyone quoting a Solomon Islands registration timeline is describing something that does not exist. Section 43 makes the British Pharmacopoeia the standard of quality and composition for all medicines, and it was re-enacted in 1978 rather than merely inherited. The Indian Pharmacopoeia is named nowhere in the Act. Import lawfulness turns on the scope of the importer's own licence, not on the product and not on the foreign plant. No CPP, GMP certificate or overseas inspection appears anywhere in the statute. For Global Fund-financed artesunate and tuberculosis injectables, WHO prequalification or an Expert Review Panel recommendation is the route. For everything else the policy defers to the standard of the country of use. Introduction: What an Injectable Manufacturer in Solomon Islands Has to Prove Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? Solomon Islands answers by not asking the question at all. There is no reliance list, and there is no product register for a reliance list to feed. The Pharmacy and Poisons Act, in force since 28 July 1941 and consolidated in the 1996 revised edition, creates a register of pharmacists and a register of premises. It creates nothing for medicines. That reframes the whole exercise. This is not a dossier market, and a supplier who offers you a registration timeline for it is describing a process that does not exist. Section 49 makes an import unlawful if the importer is not entitled under their licence to sell the thing being imported. The gate sits on the buyer, not on the product. What Sets a World-Class Injectable Manufacturer in Solomon Islands Apart Section 43 provides that the British Pharmacopoeia, in the edition for the time being in force, is the standard of quality or composition for all drugs and medicines. That is exclusive drafting — the standard, for all medicines — and it carries a detail worth noticing, because the section was re-enacted in 1978, the year of independence. Indian sterile plants routinely release to BP monographs, so this aligns well; an IP-only specification is the weak flank. The second thing to understand is where quality is actually policed, which is procurement rather than law. Public medicines move through the National Medical Store in Honiara to eighteen second-level stores and on to more than 350 service delivery points, free at the point of use. In 2023 the Ministry put bidding onto a digital platform and made expiry information and minimum delivery periods mandatory bid conditions. Those tender terms, not the 1941 statute, are where a manufacturer's certifications actually get read. Quality Systems Behind Every Sterile Injectable We Ship to Solomon Islands Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Stability follows ICH Q1A with Q1B photostability. Dossiers are built in CTD structure with ACTD available — not because Solomon Islands asks for one, but because a tender or a donor will. Two local realities shape the specification more than any rule does. Solomon Islands publishes no national stability condition; the WHO reference table places it at 30°C and 65% relative humidity, and that entry is derived from climate data rather than confirmed by the regulator, so we found no binding requirement and therefore claim none. We hold Zone IVb data because it envelopes that. And the last leg runs by boat, light aircraft and motorbike to clinics often staffed by one nurse, across nine provinces and ninety inhabited islands, which argues for long remaining shelf life far more than for cold chain. Working out whether Solomon Islands is reachable for your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Solomon Islands for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Solomon Islands we can supply WHO-format GMP and pharmaceutical product certificates, BP-referenced release data and full stability packages for a tender file. What we cannot do is import, and no certificate we hold cures that: every licence in the Act attaches to a local person and local premises. We hold no Solomon Islands licence and recommend no partner we have not verified. The binding quality gate for part of the portfolio is a donor rule rather than a national one. The Global Fund accepts WHO prequalification, a pre-2015 stringent regulatory authority, a WHO Listed Authority or its Expert Review Panel — and India's CDSCO is none of those for medicines, since WHO lists it for vaccines only. But that gate applies solely to antiretroviral, anti-tuberculosis and antimalarial finished products; for everything else the policy defers to the standard of the country of use. Malaria is why this matters here: WHO recorded 147,145 presumed and confirmed cases in 2023, with 99% of the population living in a high-transmission area, and injectable artesunate has been national policy for severe malaria since 2018. The financing picture is unusual and easy to misread. Population was 838,645 in 2025; current health expenditure was 5.36% of GDP in 2023 at US$111 per head, putting the national total near US$89 million. Out-of-pocket spending was just 3.16% — among the lowest anywhere — but that figure is partly an artefact of the 33.87% financed externally in the same year, up from 27.37% in 2022. A third of the denominator is donor money, so the low household share is not by itself evidence of financial protection. We will not print a market-size figure: the two customs series we found disagree and both look implausible against US$89 million. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Solomon Islands recognise India's CDSCO or Indian regulatory approval? There is nothing to recognise it with. No instrument names any foreign medicines regulator — not CDSCO, and equally not the TGA, MHRA, US FDA or EMA — because the Act contains no agency-recognition mechanism and no product register. Where CDSCO status does bite is inside Global Fund money, and there it does not qualify. Is the Indian Pharmacopoeia accepted in Solomon Islands? Not on any published basis. Section 43 names the British Pharmacopoeia exclusively, as the standard for all drugs and medicines, and the Act's own schedule uses BP and BPC designations throughout. This is not fatal for an Indian supplier, because BP release is standard practice in Indian sterile plants — but an IP-only specification has no statutory footing, and a supplier claiming otherwise is reading something that is not there. Does a foreign manufacturer need a local partner in Solomon Islands? Yes, unavoidably. Every authorisation in the Act attaches to a local person or body corporate operating local premises: a Medicine Licence is granted to a licensed storekeeper and names the articles that may be sold, a Poisons Licence covers one place of business, and a body corporate dealing in drugs must trade under a registered pharmacist as superintendent. A foreign manufacturer holds nothing and can hold nothing. What does registration cost in Solomon Islands, and how long does it take? Neither question has an answer, and that is the finding rather than a gap. There is no registration, so there is no registration fee and no statutory decision clock anywhere in the Act — the only figures in the statute are legacy amounts that show its age. The Government's own trade portal publishes no medicines procedure at all. Confirm current practice directly with the Ministry of Health and Medical Services. What actually controls an injectable consignment arriving in Solomon Islands today? Three things, none of them a product approval. The importer's licence scope, under section 49, which makes the import unlawful if the licence does not cover the article. A discretionary power for the Under Secretary for Health to certify goods to Customs as not to be imported. And a separate Board licence for anything on the poisons list, which for an injectable portfolio notably includes insulin. A pharmacy permit is also reported in practice, though we found no instrument establishing one. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 11, 2026 TL;DR: Guyana names the regulators it leans on — the United States, Canada, the United Kingdom and Australia — and India is not among them. But it leans harder than any other CARICOM state on the Caribbean Regulatory System, which accepts a WHO-prequalified finished product as an eligibility route. Guyana has registered 164 CRS-recommended products since October 2017, against Haiti's five. The door is open; it is simply not the door marked CDSCO. Key Takeaways Guyana's Food and Drug Department states it relies on assessments from the United States, Canada, the United Kingdom and Australia, falling back on WHO prequalification or a Caribbean Regulatory System recommendation. CDSCO appears on none of those lists. The CRS accepts WHO-prequalified finished products directly, charges US$300 per application, and currently turns dossiers around in about 60 days. A recommendation registers nothing — it converts into a national authorisation, target 120 days, with an importer named. Every one of the 210 pharmaceutical contracts in the national tender register was awarded by National Competitive Bidding. Bidder registration requires Guyanese tax, social-security and VAT identity, so a foreign manufacturer cannot bid alone. Import licences are issued per consignment, the importer must be under a pharmacist's direct control with registered premises, and stock must arrive with at least 75% of shelf life remaining. Introduction: What an Injectable Manufacturer in Guyana Has to Prove Guyana answers this series' standing question more directly than most. Its Food and Drug Department has stated that it relies on full assessment of safety, efficacy and quality from listed reference authorities — the United States, Canada, the United Kingdom and Australia — and that where those are not met it relies on WHO prequalification or a recommendation reaching it through the Caribbean Regulatory System. India's CDSCO is on none of those lists. What makes Guyana interesting is the second half of that sentence, which most supplier pages never quote. WHO prequalification is not a consolation route here; it is a named eligibility criterion. The Caribbean Regulatory System, run as a regulatory unit inside the Caribbean Public Health Agency, explicitly accepts applications for review of finished products prequalified by WHO, alongside products approved by a regional-reference or stringent authority. For an Indian manufacturer, that is the one gate whose key can be cut in Gujarat. What Sets a World-Class Injectable Manufacturer in Guyana Apart Guyana is not a marginal user of that system — it is the anchor customer. Of roughly 353 products the CRS has recommended since 2017, Guyana has registered 164, against five in Haiti and two in the Bahamas. The Acting Director of Guyana's Food and Drug Department has said on the record that the pathway runs in parallel with national registration and has provided an efficient alternative during periods of high workload, when meeting the 120-day processing timeline may be challenging. The practical economics are modest and knowable. A CRS application costs US$300 for a manufacturer or marketing-authorisation holder, or US$150 where a local importer submits — the lower fee deliberately pushes manufacturers to file through importers. A decision is due within 90 calendar days of dossier acceptance, with a current turnaround reported at around 60, and a recommendation is valid for five years. But a recommendation registers nothing by itself: converting it into a lawful authorisation means a national application form, the CRS assessment report and certificate, the national fee, and a named importer — a target of 120 days. Quality Systems Behind Every Sterile Injectable We Ship to Guyana Guyana's door is opened by WHO prequalification or a stringent-authority approval, so the work sits in the plant. Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials, and stability follows ICH Q1A with Q1B photostability. Two Guyanese requirements should be designed in rather than discovered late. Stock must arrive with at least 75% of its stated shelf life remaining, which argues for fresh manufacture against a confirmed order. And labelling must be in English — brand name, generic name, manufacturer address and the patient leaflet — with foreign-language labelling liable to seizure. Dossiers are assembled in CTD format, with ACTD available where a regulator prefers it; we found no published Guyanese dossier-format guideline and therefore assert none. Working out whether the CRS route fits your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Guyana for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Guyana we can build the dossier and supply the WHO-format certificate of a pharmaceutical product and GMP certificate. What we cannot do is import or bid. The importer must be a Guyanese business under a pharmacist's direct control, with registered premises, holding a licence valid only for the particular importation it was issued for. We hold no Guyanese registration and recommend no distributor we have not verified. Anyone pitching Guyana on tender volume should look at how those tenders are actually let. Across the whole published award register, all 210 pharmaceutical and medical-supply awards were made by National Competitive Bidding and none by international bidding, and bidder registration requires Guyanese tax, social-security and VAT identity. Injectables are not tendered under that name either — they sit inside lotted pharmaceutical supply tenders, visible only in the lot schedules. One route needs no local agent: the regional health body's pooled funds — but they rest quality assurance on WHO prequalification and on regulators they recognise. Read Guyana's economics carefully, because the headline indicator lies. Current health expenditure was 2.47% of GDP in 2023 — down from 4.90% in 2019 — which reads like retrenchment and is the opposite. Per-capita health spending rose over the same period from about US$314 to about US$505; the ratio collapsed because oil took the denominator up more than sixfold. Population was about 836,000 in 2025, though the 2022 census counted 878,674 — about 7% above the estimate series every per-capita figure divides by. Two live items belong in any plan: Guyana is drafting new medicines legislation, so the 1971 framework is mid-replacement, and a Life Sciences Park with European backing explicitly contemplates domestic pharmaceutical and vaccine manufacturing. We print no registration fee, because none is published. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Does Guyana accept Indian regulatory approval for medicines? Not as a recognised approval. Guyana's Food and Drug Department has stated it relies on assessment from the United States, Canada, the United Kingdom and Australia, with WHO prequalification or a Caribbean Regulatory System recommendation as the fallback. CDSCO appears on none of those lists, and its WHO maturity-level-3 and transitional listed-authority status is scoped to vaccines, not medicines. The workable route for an Indian manufacturer is WHO prequalification or an approval from a recognised authority. Is the Indian Pharmacopoeia recognised in Guyana? This needs care, because two things are true at once. The Indian Pharmacopoeia Commission signed a memorandum of understanding with Guyana's health ministry in November 2024 recognising the Indian Pharmacopoeia as a compendium of standards. But the drug standards schedule to Guyana's Food and Drugs Act lists eight pharmacopoeias and the Indian Pharmacopoeia is not among them, and we found no amendment adding it. Treat it as recognised by memorandum, not as settled in statute. Does a Caribbean Regulatory System recommendation register my product in Guyana? No, and CARPHA is explicit about it. A recommendation is an assessment outcome member states may rely on; when a state decides to register or import, its own process still applies. In practice that means a national application form, the CRS assessment report and certificate of recommendation, payment of the national fee, and identification of an importer, with a target of 120 calendar days. Can an Indian manufacturer supply Guyana's public sector directly? Not by bidding. Every pharmaceutical award in the published tender register was made by National Competitive Bidding, and bidder registration requires Guyanese tax, social-security and VAT registration, so a foreign manufacturer needs a locally registered partner. The one channel that does not require a local agent is regional pooled procurement — which applies its own quality gate, resting on WHO prequalification. What does registration cost in Guyana, and how long does it take? We can give one figure and not the other. The Food and Drug Department's published processing timeline is 120 days, and its Acting Director has acknowledged that meeting it can be challenging under workload. On fees we found no published schedule for national registration and will not invent one. The CRS fee is published and is US$300 per medicine application, or US$150 where a local importer submits. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 11, 2026 TL;DR: The Comorian rulebook is eight days old. On 3 September 2026 ANAMEV published, for the first time in one place, eleven CTD dossier checklists, the marketing-authorisation form and five governing decisions. A decision is due within 90 days — but the clock starts when fees are paid, and the fee schedule is published nowhere. The commercial route is narrower still: the national list of licensed wholesalers has exactly one entry. Key Takeaways ANAMEV published its complete marketing-authorisation requirements on 3 September 2026. Any guidance on Comorian registration written before that date describes a different regime. Décision N°012 adopts mutual recognition and the WHO Collaborative Registration Procedure — then names no authority at all, and CDSCO appears nowhere. WHO prequalification of the active ingredient is the one mechanism that measurably shortens the dossier. OCOPHARMA is the only licensed wholesaler in the country, serving 25 licensed pharmacies across three islands. Representing your products requires a pharmacien-conseil resident in the Comoros who is jointly liable alongside you. Today the control that actually binds is customs, not registration: a per-consignment import licence cleared in four working days, then physical inspection that names injectable medicines as its own category. Introduction: What an Injectable Manufacturer in Comoros Has to Prove Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? The Union of the Comoros answers in a way no earlier market has, because its answer is eight days old. On 3 September 2026 the Agence Nationale des Médicaments et des Évacuations Sanitaires published eleven CTD dossier checklists, the marketing-authorisation form and five governing décisions. Before that, the regime existed only on paper under the 2020 Code de la Santé Publique. Read what it says rather than what it suggests. Article 10 of Décision N°012 adopts the principle of mutual recognition and implements the WHO Collaborative Registration Procedure — and then names no authority. There is no reliance list and no mention of CDSCO anywhere in ANAMEV's published set. What is named is narrower and more useful to a manufacturer: a country-of-origin marketing authorisation or a WHO-format Certificate of a Pharmaceutical Product, a WHO-format GMP certificate, bioequivalence data, and a French-language summary of product characteristics on the WHO model. The only pharmacopoeia named anywhere is the European one. What Sets a World-Class Injectable Manufacturer in Comoros Apart The one place the new rulebook offers genuine leverage is WHO prequalification. Where the active ingredient is WHO-prequalified, parts of Module III fall away: container-closure data is not required, and manufacturing information is required only where finished-product sterility depends on the active ingredient. That is the closest thing to an abridged pathway in the Comorian system, and it is earned in a laboratory rather than negotiated in a meeting. Against that sits an arithmetic problem worth stating plainly. Article 11 gives ANAMEV a maximum of 90 days to grant or refuse a new authorisation — but the clock starts on the date the fees are paid, and we could find no published fee schedule to pay against. The file must also pass the Commission Nationale d'Homologation des Produits Pharmaceutiques and a technical expert committee, each of which ordinarily meets once a quarter. A 90-day maximum gated behind two quarterly calendars is a planning constraint, and a supplier who offers a firm date should be asked how they arrived at it. Quality Systems Behind Every Sterile Injectable We Ship to Comoros The dossier ANAMEV now asks for is largely the dossier a serious sterile plant already generates. Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Stability follows ICH Q1A with Q1B photostability, on the climatic zone an equatorial island destination actually requires. Two Comoros-specific details change how the file is assembled. The summary of product characteristics must be in French and follow the WHO model — a translation workstream to be scheduled, not an afterthought at submission. And the generic route requires bioequivalence or comparative dissolution data as a matter of course. Dossiers are built in CTD structure, with ACTD available where a regulator prefers it; we found no Comorian requirement for eCTD and therefore claim none. Working out whether Comoros is reachable for your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Comoros for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Comoros we can build the CTD dossier, supply the WHO-format CPP and GMP certificate, generate bioequivalence and stability data, and prepare the French RCP. What we cannot do is import. ANAMEV's published list of licensed wholesalers contains exactly one entry — the state-owned OCOPHARMA in Moroni — against 25 licensed pharmacies in the whole country. We hold no Comorian registration and recommend no partner we have not verified. Representation is regulated separately and more heavily than most exporters expect. Under Décision N°007, a medical promotion or representation agency must retain a pharmacien-conseil who resides in the Comoros and is registered with the Ordre National des Pharmaciens, and that pharmacien-conseil is jointly liable, criminally included, alongside the agency. The commercial gate is tighter than the technical one. And for the malaria, HIV and tuberculosis volumes that dominate donor spending, a second gate sits above both: the Global Fund's quality-assurance policy accepts WHO prequalification, a pre-2015 stringent regulatory authority, a WHO Listed Authority, or its Expert Review Panel — and India's CDSCO is none of those for medicines, since WHO lists it at maturity level 3 for vaccines only. The numbers are small and the honesty about them matters more than the size. Population was 866,628 in 2024 on World Bank figures; current health expenditure was 6.55% of GDP in 2023, with 56.57% paid out of pocket and 26.77% financed externally, on WHO Global Health Expenditure Database data. That external share was 43.30% a year earlier — households, not donors, absorbed the swing. We will not print a market-size figure: the two mirror-trade sources we found differ by roughly five times. Nor will we print a registration fee, because none is published. One caveat we would rather state than hide: OCOPHARMA's own quality lead listed non-registration among the system's live gaps in 2024, and WHO's 2024–2028 country strategy records essential-medicine availability at 28%. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Does Comoros recognise India's CDSCO or Indian regulatory approval? We found no Comorian instrument naming CDSCO, and no published list of recognised foreign regulators. Décision N°012 adopts mutual recognition as a principle and implements the WHO Collaborative Registration Procedure, but names no authority to recognise. What ANAMEV does require is a country-of-origin marketing authorisation or a WHO-format Certificate of a Pharmaceutical Product, plus a WHO-format GMP certificate — requirements about document format, not about which agency issued the approval. Is the Indian Pharmacopoeia accepted in Comoros? Not as far as any published document shows. The only pharmacopoeia named in ANAMEV's dossier requirements is the European Pharmacopoeia, through a certificate of suitability. Specifying to an Indian Pharmacopoeia monograph is not prohibited and may be entirely appropriate for the molecule — but nothing in the Comorian rulebook gives it recognised status, and a supplier claiming otherwise is reading something that is not there. Does a foreign manufacturer need a local partner in Comoros? Effectively yes, on two counts. Importing requires an establishment registered with ANAMEV holding a one-year import approval, and ANAMEV's published wholesaler list has a single entry. Separately, promoting or representing your products requires a ministerially authorised agency retaining a pharmacien-conseil resident in the Comoros and registered with the Ordre National des Pharmaciens, who carries joint liability. Neither route lets an overseas manufacturer act alone. What does registration cost in Comoros, and how long does it take? We will print a timeline and not a cost. Décision N°012 sets a maximum of 90 days for a decision on a new application and on a renewal, with renewals filed at least three months before expiry. But the 90 days run from the date fees are paid, and we could find no published fee schedule — the amounts are set by decisions of ANAMEV's Director-General that are not on the public record. Confirm both with ANAMEV directly. What actually controls an injectable consignment arriving in Comoros today? Customs, in practice. Every import needs a prior ANAMEV licence requested through the SYDONIAWorld system, with a published processing time of four working days and a fee of 10,000 KMF. On arrival a separate release authorisation applies: documentary inspection within 48 working hours, then physical inspection at the port or airport, under procedures that name injectable medicines as their own inspection category. Thermolabile and biological products can move under a provisional release. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Top Injectable Manufacturer in Fiji – Reliable Pharmaceutical Solutions Last Updated: September 10, 2026 TL;DR: Fiji publishes exactly which foreign regulators it recognises, and India is not among them. For government supply, the regulator's own routing table says a product both registered and manufactured outside a PIC/S country is not accepted for prequalification. The open doors are WHO prequalification of the product, or a marketing authorisation from a stringent or WHO-listed authority — a solvable engineering problem, not a closed market. Key Takeaways Fiji recognises regulators that WHO designates as stringent or WHO-listed, the New Zealand regulator, and regulators of PIC/S member countries; India is in none of those categories. CDSCO does appear on WHO's maturity-level listing, but the scope recorded against it is vaccines — it is not a medicines credential for a sterile injectable. WHO-GMP certified and WHO prequalified are different things, and Fiji asks for two GMP certificates when the site sits in a country it does not recognise. Government supply and the private market are separate doors with separate rules, and prequalification is not by itself an order from the health ministry. Introduction: What an Injectable Manufacturer in Fiji Has to Prove Fiji is the most legible market this series has examined, and the legibility cuts both ways. The Medicines Regulatory Authority's prequalification guidance of March 2024 states which regulators it recognises: those WHO designates as stringent or WHO-listed authorities, the regulator of New Zealand, and the regulators of countries belonging to PIC/S, with a residual discretion to consider others case by case. India appears in none of the three named limbs, and India is not a PIC/S member. It is worth being precise about the one place India does appear, because it is easy to over-read. CDSCO is on WHO's transitional listed-authority register at maturity level 3 — but the scope recorded against it is vaccines. Every authority whose scope reads medicines and vaccines qualifies for a sterile injectable; an entry scoped to vaccines does not. Separately, the Indian Pharmacopoeia Commission signed a memorandum with Fiji's health ministry in Suva in May 2025 recognising the Indian Pharmacopoeia as one of the standards for Indian-made products used in Fiji. That is recognition of a book of standards, not of an agency, and we found no Fiji-side instrument implementing it. What Sets a World-Class Injectable Manufacturer in Fiji Apart The regulator publishes a routing matrix, and one row decides the question for most Indian exporters: a product registered in a non-PIC/S country and manufactured in a non-PIC/S country is not accepted for prequalification. That is India to India, in the Authority's own words rather than by our inference, with a shortage-based case-by-case exception as the only stated relief. A second requirement sharpens it. Where the manufacturing site sits in a country Fiji does not recognise, the guidance asks for two GMP certificates — the local one, plus one issued by a regulator Fiji does recognise — and points applicants at the European GMP database. A WHO-GMP certificate from an Indian state licensing authority satisfies the first of those and not the second. So the honest answer is that the ordinary route is closed and two specific doors are open. The first is WHO prequalification of the finished product, where the guidance makes the country of manufacture explicitly irrelevant. The second is a marketing authorisation held in a country whose regulator Fiji recognises — an EU member state, the United Kingdom, Australia, Japan, Canada, Switzerland, the United States or New Zealand — after which the Indian origin of the site stops being the deciding fact. Both are multi-year investments rather than paperwork, and a manufacturer that tells a Fijian buyer otherwise is not being straight with them. Quality Systems Behind Every Sterile Injectable We Ship to Fiji Those two doors are reachable from the same quality system, which is why the investment compounds. Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic processing or terminal sterilisation, media fills and environmental monitoring. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for endotoxins and Karl Fischer for moisture in lyophilised vials. Stability runs on ICH Q1A protocols with Q1B photostability, on the climatic zone for a humid tropical Pacific destination rather than a temperate default. Dossiers are assembled in CTD format, with ACTD available where a regulator prefers it, which is the format both a WHO prequalification submission and a stringent-authority filing are built from. One practical detail surprises people: Fiji expects the pack presented to it to be identical to the pack approved in the reference market. The instinct to design a Fiji-specific carton is wrong, and rebuilding artwork late is a common cause of avoidable delay. Working out which door into Fiji fits your product? Talk to our regulatory team about prequalification dossiers, reference-market strategy and pack-identity requirements. Why Farbe Firma is the Trusted Injectable Manufacturer in Fiji for Global Buyers Fiji has two doors, not one, and conflating them causes most of the confusion we see. For government supply, an overseas supplier may apply to the Authority directly; the manufacturer and the product are prequalified separately, and goods imported by Fiji Pharmaceutical and Biomedical Services against a prequalification are exempt from per-shipment import permits. For the private market, the applicant is a locally registered and licensed Fijian entity, which lists the product and holds the import permit — and that listing is applicant-specific and not transferable without the Board's approval, a real commercial lock-in worth weighing when a distributor is chosen. We would add that the evidentiary requirements published in the prequalification guidance are written for prequalification, and a manufacturer should confirm with the Board what applies to a private-market listing rather than reading one across to the other. The buyer is also not always the ministry. For HIV and tuberculosis commodities the operative purchaser under a health-procurement project signed in July 2024 is UNDP, applying the Global Fund's quality-assurance policy, which accepts WHO prequalification, a stringent authority, a WHO-listed authority, or expert-review-panel review. UNFPA's Pacific presence is based in Fiji, with the national warehouse acting as a node for several countries. These donor rules are frequently the gate that actually binds, and they point at the same two doors as the national regulator: solving for WHO prequalification solves for several buyers at once. The market itself is modest. The population stood at 928,784 in 2024, current health expenditure at 3.62% of GDP in 2023, with 8.31% paid out of pocket and 11.64% financed externally, all on WHO Global Health Expenditure Database figures. We would caution against reading trends into that series: a 2021 spike reflects a pandemic-era GDP denominator, and a later movement in the out-of-pocket share reflects a methodology change. On costs and timelines we print nothing: no fee schedule and no statutory processing time appears in the Act, the regulations or any of the guidance documents we read. One further correction, because it circulates widely: the twelve-month shelf-life-on-arrival rule often quoted here is India's import rule, not Fiji's, and we found no Fijian equivalent. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Fiji accept Indian regulatory approval for medicines? Not as a recognised approval. Fiji recognises WHO-designated stringent and WHO-listed authorities, the New Zealand regulator, and regulators of PIC/S member countries, and India falls into none of those. The Authority's own routing table records that a product registered and manufactured in a non-PIC/S country is not accepted for prequalification, with a shortage-based exception decided case by case. Is WHO-GMP certification enough to supply Fiji? No, and the distinction matters. WHO-GMP certification is a GMP credential issued by an Indian licensing authority; WHO prequalification is an assessment of a specific product by WHO. Where the site is in a non-recognised country, Fiji's guidance asks for a second GMP certificate issued by a regulator it does recognise, which a WHO-GMP certificate does not supply. Does the Indian Pharmacopoeia memorandum open a registration pathway in Fiji? No. The memorandum signed in Suva in May 2025 recognises the Indian Pharmacopoeia as one of the standards for Indian-made products used in Fiji. That is a book of quality standards, not an agency recognition, and waives no registration requirement. We found no Fiji-side implementing instrument, and the Authority's guidance still names the British, European, International and United States pharmacopoeias. Does a foreign manufacturer need a local agent in Fiji? It depends on the door. For government supply an overseas supplier may apply for prequalification directly. For the private market the applicant must be a locally registered and licensed Fijian entity, which then owns the listing and holds the import permit — so a blanket claim that a local agent is always legally required would be wrong, and so would the opposite. What do registration and prequalification cost in Fiji, and how long do they take? We will not print a figure for either. No fee schedule and no statutory timeline appears in the Medicinal Products Act, its regulations, or any of the Authority's guidance documents we were able to read. Both should be confirmed with the Authority directly, and any plan that depends on a date should be built after that confirmation. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Farbe Firma Pvt Ltd — WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. Exporting to 30+ countries. Email: director@farbefirma.org | Request a Quote / View Products / FAQ / Blog

Top Injectable Manufacturer in Djibouti – Reliable Pharmaceutical Solutions Last Updated: September 10, 2026 TL;DR: Djibouti publishes no list of foreign regulators it trusts. Its 1991 medicines law applies a country-of-origin test instead: an imported speciality may be registered only if it is already registered where it was made. That is unusually open to an Indian manufacturer — but the Ministry of Health's own strategy records that the registration system is not operated, so the gates that bind are the import visa, the pharmacist monopoly on importing, and CAMME's tenders. Key Takeaways Djibouti's Law 145/AN/91 requires an imported speciality to be registered in its country of origin; no foreign agency is named, so India is neither listed nor excluded. The Ministry of Health's supply strategy, adopted by Law 14/AN/23 of 10 March 2024, states that the registration system is not applied — the control point in practice is the import visa. Only pharmacists may import and wholesale medicines, so a foreign manufacturer cannot import in its own name and must work through a licensed local establishment. Djibouti participates in IGAD's medicines-harmonisation initiative, whose secretariat sits in Djibouti City and which shares joint WHO cGMP inspections between seven regulators. Introduction: What an Injectable Manufacturer in Djibouti Has to Prove This series usually opens by asking whether a country recognises the Indian regulator. Djibouti answers differently: it publishes no list of foreign agencies at all. Article 8 of Law 145/AN/91 of 10 February 1991 says instead that imported specialities may be registered only if they have already been registered in their country of origin, and Article 88 of Law 48/AN/99 makes the parallel demand of generics — that they be legally marketed in the producing country. The test is about where a product comes from, not about who approved it. For a Gujarat manufacturer that framing is structurally favourable: there is no list to get onto and none to be excluded from, and the burden is purely evidentiary. Djibouti is also a listed participant in the WHO Certification Scheme, which makes a WHO-format Certificate of a Pharmaceutical Product the recognised instrument for carrying that proof. But the openness has a counterpart that any serious supplier should understand before quoting: the register this law describes is, on the Ministry of Health's own account, not currently being operated. What Sets a World-Class Injectable Manufacturer in Djibouti Apart The Ministry's pharmaceutical supply strategy, adopted by Law 14/AN/23 of 10 March 2024, states plainly that the registration system run by the medicines directorate is not applied, and its action plan lists drafting the medicines-registration regulation as the first activity to complete. We could not find an implementing decree for the 1991 law's procedural articles, and we found no published fee schedule and no published timeline anywhere. Where a market's own sources leave those numbers unstated, we print neither and confirm both with the directorate. So the constraint that actually binds sits elsewhere, and it sits on the importer rather than on the factory. Article 2 of the 1991 law reserves the import, wholesale and supply of medicines to pharmacists, and Article 4 adds a nationality-or-reciprocity condition together with registration on the professional roll. A 2024 ministerial decree sets out the sequence an establishment must follow — approval, provisional authorisation, an inspection of conformity, then definitive authorisation, with annual re-inspection. The consequence is unambiguous: Farbe Firma cannot import into Djibouti in its own name, and the quality of a Djiboutian partner is the licence itself, not a commercial detail. We should also flag what we could not establish: no decree we found specifies whether the manufacturer or the local agent owns a Djiboutian marketing authorisation, and that question should be put to the directorate rather than assumed. Quality Systems Behind Every Sterile Injectable We Ship to Djibouti Because the country-of-origin test asks what the product is at home rather than who signed off abroad, the dossier has to carry its own weight. Every batch Farbe Firma releases is manufactured under WHO-GMP certification in ISO Class 5 filling environments, with terminal sterilisation or validated aseptic processing, media fills and environmental monitoring. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised presentations. Stability runs on ICH Q1A protocols with Q1B photostability, on the climatic zone appropriate to a Red Sea port rather than a temperate default. Documentation is assembled in CTD format, with ACTD available where a buyer's regulator prefers it, so one dossier can serve a Djiboutian filing, a regional submission and a donor qualification. That matters more here than in most markets: Djibouti has no national quality-control laboratory and no national pharmacovigilance centre, and its own strategy records that it is not a member of the WHO Programme for International Drug Monitoring. The manufacturer's own quality system is therefore doing work a domestic laboratory does elsewhere. Planning a shipment into Djibouti or onward to the Horn of Africa? Talk to our export team about dossier formats, CoPP issuance and cold-chain routing through the Port of Djibouti. Why Farbe Firma is the Trusted Injectable Manufacturer in Djibouti for Global Buyers Djibouti is a small market attached to a very large corridor, and the two need separate answers. Domestically the numbers are modest: the World Bank puts the population at 1,168,722 in 2024, current health expenditure at 2.28% of GDP in 2023, with 28.84% paid out of pocket and 23.60% financed externally. Public purchasing runs largely through CAMME, the central medical stores, whose 2025 forecast budget, set out in a 2024 ministerial order, shows a medicines-sales line of 395,000,000 Djiboutian francs. We could not reconcile that line with the 1.48 billion franc medicines purchase budget reported for 2020 in the Ministry's own strategy; the two published figures conflict, and we print both rather than choosing. The corridor is the other half of the picture. Djibouti's port handles the overwhelming majority of landlocked Ethiopia's trade, and transit clears under a regime distinct from domestic entry: medicines entering Djibouti's own market require the Ministry of Health's visa, while goods bound onward answer to the destination regulator. For that flow the authority that matters is Ethiopia's EFDA, which WHO lists at maturity level 3 for medicines. This corrects a common assumption — India's CDSCO does appear on WHO's maturity-level listing, but the scope column reads vaccines only, so it is not a medicines credential in any market that reads that list carefully. Finally, the regional route is real, and it is administered from Djibouti City. Djibouti is one of seven regulators in IGAD's medicines-harmonisation work, which accepts dossiers in ICH CTD format, shares joint WHO cGMP site inspections between members for reliance purposes, and asks applicants to commit to marketing in at least two member states. IGAD recommends rather than approves — each authority still issues its own marketing authorisation — and IGAD itself labels its published timelines indicative. Farbe Firma's range maps closely onto the initiative's priority list, which includes oxytocin, magnesium sulphate, tranexamic acid and fixed-dose antimicrobials. Djibouti has neither signed nor ratified the African Medicines Agency treaty, so AMA is not a route here today. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Djibouti recognise Indian regulatory approvals such as CDSCO? Not in those terms. We found no list of recognised foreign agencies in Djiboutian law. The 1991 law requires that an imported speciality already be registered in its country of origin, which an Indian registration satisfies on its face. India is neither named nor excluded: the test is about origin, not about the approving agency. Is the Indian Pharmacopoeia accepted in Djibouti? We cannot say, in either direction. Djiboutian law provides for a ministerial order listing the pharmacopoeias that may be referenced and prohibits reference to any other. We were unable to locate that order, so whether the Indian Pharmacopoeia appears on it is unknown to us. Farbe Firma releases to USP, BP, IP or EP as a buyer requires. Can Farbe Firma import into Djibouti directly? No. Djiboutian law reserves the import, wholesale and supply of medicines to pharmacists, with a nationality-or-reciprocity condition and registration on the professional roll, and a 2024 decree sets out the approval and inspection sequence an establishment must complete. A foreign manufacturer supplies through a licensed local establishment or to CAMME, not in its own name. What does registration in Djibouti cost, and how long does it take? We are not going to print a number for either. No fee schedule and no statutory timeline were found in any published Djiboutian instrument we could read, and the Ministry's own strategy records that the registration regulation is still to be drafted. Both should be confirmed with the medicines directorate before a launch plan depends on them. Does Farbe Firma supply the Ethiopia transit corridor through Djibouti? Yes, and the two flows are worth separating. Goods entering Djibouti's domestic market need the Ministry of Health's import visa; goods in transit to Ethiopia answer to Ethiopia's EFDA, which WHO lists at maturity level 3 for medicines. Because both countries participate in IGAD, a single CTD dossier and a shared cGMP inspection can serve both ends of the corridor. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Farbe Firma Pvt Ltd — WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. Exporting to 30+ countries. Email: director@farbefirma.org | Request a Quote / View Products / FAQ / Blog

Last Updated: September 9, 2026 TL;DR: Eswatini is the market where our standing question stops working. We ask whether a country names the foreign regulators it leans on; Eswatini has not been operating a national registration system at all, so there is no decision for a foreign decision to be leaned into. The Ministry of Health's own 2021 policy says the country "is currently not actively registering medicines". What exists instead is a certificate test sitting on the import permit, and it is agency-agnostic: produce the product registration certificate from the regulator in the country of origin, whoever that regulator is. Key Takeaways There is no list, and no register either. We found no published Eswatini list of recognised foreign regulatory authorities and no instrument naming CDSCO, to recognise or to exclude it. The Ministry's 2012 import guideline requires product registration certificates for the medicines to be imported, "issued by the relevant authorities in the country of normal origin", plus batch analysis certificates. On its face an Indian certificate meets that description; we found no Eswatini statement confirming it in practice. The Act exists; commencement could not be confirmed. The Medicines and Related Substances Control Act (Act 9 of 2016; the short-title clause reads "2015") provides for a Medicines Regulatory Authority, but section 1(2) brings it into force on a date appointed by the Minister in the Gazette — we found no commencement notice and could not access a searchable Gazette. The Authority's board was reported unveiled on 8 January 2026, with no register, no finalised regulations and no quality-control laboratory behind it. The binding constraint is the importer, decisively. Imports must run through the Ministry or through authorised pharmaceutical importers registered with it; the criteria are suitable warehousing premises and suitably qualified pharmaceutical personnel, and the certificate names a supervising pharmacist. Permit validity shall not exceed six months, and no importation of medicines may be done by post. The gate that actually bites is a donor rule, not an Eswatini rule. About 28% of current health expenditure was external money in 2023, and the Global Fund's Quality Assurance Policy requires WHO prequalification, an SRA, a WLA or ERP review for antiretroviral, anti-tuberculosis and antimalarial products — its ERP route requiring GMP verified by WHO-PQ, an SRA or WLA, or a PIC/S authority, which is where India's PIC/S non-membership tells. Introduction: Why Eswatini Demands a Premium Injectable Manufacturer in Eswatini Every market in this series opens by asking whether the country publishes a list of foreign regulatory authorities it will lean on, and whether India's CDSCO is among them. Eswatini is the first where the honest answer is that the question does not fit. The Ministry of Health's National Pharmacovigilance Policy of June 2021 states that the country "is currently not actively registering medicines", and that suppliers are registered as importers and issued an import certificate while "these products are not considered as being registered". There is no registration decision into which a foreign decision could be leaned. What operates in its place is a documentary test at the border, and it is agency-agnostic. The 2012 import guideline asks for the product registration certificate issued by "the relevant authorities in the country of normal origin" — open-ended, with no list of acceptable authorities anywhere in it. The Ministry's own medicines database asks which authority registered a product without restricting which authorities count. So an Indian certificate is, on the published documents, the same kind of object as anyone else's. We found no statement confirming that in practice, and a serious injectable manufacturer in Eswatini does not upgrade a silence into a permission. What Sets a World-Class Injectable Manufacturer in Eswatini Apart Site rules and product rules must be kept apart: on the statute book both exist, and in practice neither operates as written. Part VI of the 2016 Act provides for manufacturer, wholesaler and import or export licences, issued on conditions relating to good manufacturing and distribution practices, valid for not more than three years. But the licensing subjects are defined by reference to premises licensed under the Pharmacy Act, 1929 — and the text of that Act we read registers chemists as persons and contains no premises-licensing provision we could identify. We found nothing creating a foreign-site licence or an overseas GMP inspection programme. So a WHO-GMP certificate is commercially and donor-relevant here rather than legally operative. We found no Eswatini legal instrument that requires it, evaluates it, or confers status on it; it is in neither the 2012 guideline's document list nor the published tender advert — though the Instructions to Tenderers is not downloadable and we could not obtain it, so that is "not stated in the advert", never "not required". Nor is there a national quality-control laboratory: reporting in 2026 describes incoming stock checked by visual inspection. Quality Systems Behind Every Injectable Supplied to Eswatini With no national dossier standard published, the discipline has to come from the manufacturer's own systems and the channels that do impose one. We found no published Eswatini dossier-format requirement — section 24(2) of the Act defers the content of an application entirely to the Authority or to regulations, and we found no evidence regulations have been finalised — so CTD and ACTD are what a serious supplier brings, not what Eswatini demands. That means aseptic process simulation for the ISO Class 5 filling line, environmental monitoring, container-closure integrity, sterility and LAL endotoxin testing, and validated HPLC and GC methods, with ICH Q1A and Q1B stability behind them. On stability, report the position rather than a number. We found no Eswatini-published stability guideline. A SADC annexure reproduced in Zambia's stability guideline, derived from a WHO table updated 1 February 2013, assigns Swaziland long-term conditions of 25 °C and 60% relative humidity — Climatic Zone II. Do not read that as a relaxation: a supplier covering neighbouring SADC markets would in practice generate 30 °C and 75% data, and be right to. Eswatini is a non-active ZaZiBoNa member, does not appear on WHO's ML3 or ML4 list, is not a PIC/S participating authority, and has not signed the African Medicines Agency Treaty. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Eswatini for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. We hold no Eswatini registration, licence or accreditation and claim none. What we supply is what the published route asks for: the Indian product registration certificate, the batch certificate of analysis, full manufacturer particulars, and the product data the import permit needs. The rest sits with a locally authorised importer holding Ministry registration, compliant warehousing and a named supervising pharmacist. Public tendering is a separate track, and the common assumption about it is wrong. Section 39 of the Public Procurement Act 2011 prohibits excluding a tenderer on grounds of nationality, and the national Standard Tender Document states that all countries are eligible and that the provider's nationality does not determine the goods' origin. A Swati agent is a price-preference lever, not an access gate: an unrepresented foreign bidder can be evaluated at up to 15% above its actual price, and partnering caps that at 7.5%. The barriers are physical, not legal — sealed paper bids to the Treasury Tender Box in Mbabane — and bidders must enclose a Manufacturer's Authorisation. Three market facts, each with its basis. Roughly 28 cents in every health dollar was donor money in 2023, so a large slice of the medicines market is donor-procured rather than government-tendered — and for antiretroviral, TB and antimalarial products the Global Fund gate applies, which CDSCO's vaccines-only ML3 scope and India's PIC/S non-membership do not open. Population carries its basis: the 2017 census enumerated 1,093,238 and the World Bank estimate for 2025 is 1,256,174, so every per-capita figure rests on projection. And the bilateral ground is better than the paperwork suggests — about 2,000 Indians live in Eswatini, around 90% of them from Gujarat. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Does Eswatini accept Indian CDSCO product registration? We found no Eswatini instrument that names CDSCO, to recognise or to exclude it. The published import guideline requires the product registration certificate issued by the authority in the country of origin, without naming which regulators qualify; on its face an Indian certificate meets that description. We found no statement confirming this in practice, and a Ministry communications officer has been quoted saying suppliers must source from accredited manufacturers, with orders from manufacturers not on the list rejected. We found no published list, criteria or statutory basis for that, and it rests on a single secondary source. Who is Eswatini's medicines regulator today? Regulatory functions have in practice been carried out by the Medicines Regulatory Unit within the Ministry of Health. The Act establishes a Medicines Regulatory Authority, whose board was reported unveiled on 8 January 2026 by two Eswatini outlets; we found no primary or official-government confirmation, and no evidence the Authority has begun registering medicines. Eswatini media use both "MRA" and "EMRA"; no primary source we found uses "EMRA". Do not confuse this with EMSA, the Eswatini Medical Supplies Agency, a supply-chain body and not a regulator. Is a CPP or a GMP certificate required to supply Eswatini? We found no published Eswatini requirement for either. The 2012 guideline's introduction stresses the WHO Certification Scheme, but the Certificate of a Pharmaceutical Product does not appear in its actual documentation requirements — what it requires is the country-of-origin registration certificate and batch analysis certificates. A GMP certificate is likewise absent from the document list and the published tender advert. Both statements are about what the published documents say; the Instructions to Tenderers could not be obtained, and regulations under section 72 could impose either. Does a ZaZiBoNa approval let you sell in Eswatini? No. ZaZiBoNa is a collaborative registration initiative that issues recommendations from joint assessment; its own site states those can be used to support registrations at country level. Registration remains a national act, and Eswatini is not currently registering medicines, so there is nothing for a recommendation to convert into. Eswatini is a non-active member — active status requires assessment and GMP inspection capacity. It may become relevant later; it is not a route into Eswatini today. What can Farbe Firma actually do for a partner supplying Eswatini? Manufacture, and supply the documents the route asks for. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. We prepare CTD and ACTD dossiers, provide the Indian registration certificate, batch certificates of analysis, WHO-format CPP and GMP certificate, and ICH Q1A and Q1B stability data. We work through a locally authorised importer, and we make no claim to be registered, listed or accredited in Eswatini. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog